Skip to main content
UniHealth

Doctor search

Sunil A Reddy, MD

Medical Oncology · Stanford

NPI 1578645057

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
5
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Reddy’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Plans whose provider directory lists this clinician
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A61643 · Current

Licensed to practise in California · since 1997 · expires 2028-08-31 · University of California, Irvine College of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$146,585

Medicare paid this office $146,585 for 311 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)122$41,147$164
Long return visit (40+ min)99$31,836$124
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes80$25,035$104
Return visit (30+ min)58$14,937$86
Return visit (30+ min)77$12,322$116
See all 9 services
Every Original Medicare service billed
Long return visit (40+ min)122$41,147$164
Long return visit (40+ min)99$31,836$124
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes80$25,035$104
Return visit (30+ min)58$14,937$86
Return visit (30+ min)77$12,322$116
Initial hospital care with moderate level of medical decision making at least 75 minutes39$6,110$153
Hospital discharge day management, more than 30 minutes57$5,850$103
New patient visit (60+ min)27$4,403$163
Short return visit (20+ min)14$1,359$85

Who their Medicare patients are

311 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 13% · Women 39% · Also on Medicaid 19% · Health risk score 2.58. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 69% · Coronary heart disease 34% · Cancer 31% · Atrial fibrillation 30% · Diabetes 28% · Chronic kidney disease 28% · Depression 24% · Heart failure 20% · COPD 14% · Dementia 12% · Stroke 12%.

The office billed $574,698, Medicare allowed $189,679 and paid $146,585; for 1,208 services of 14 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20243111,208752.58$574,698$146,585
20233161,136752.66$497,253$134,279
20223511,146752.55$507,783$132,261
20213601,285742.32$520,910$139,667
20202561,006742.50$358,324$88,694
2019256965742.42$196,705$92,636
2018257925732.26$201,376$87,297
2017229818732.35$202,630$71,692
2016212586732.56$170,503$53,212
2015144407732.33$113,467$37,617
2014143347711.66$99,534$32,678
201383257731.94$70,870$22,863

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)158$62,243$132
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes84$27,286$108
Return visit (30+ min)107$19,921$89
Initial hospital care with moderate level of medical decision making at least 75 minutes60$9,756$160
New patient visit (60+ min)54$8,571$159
Hospital discharge day management, more than 30 minutes40$4,284$107

2022: 7 services

Original Medicare services billed in 2022
Long return visit (40+ min)161$59,471$128
Return visit (30+ min)97$19,710$86
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes69$17,174$93
New patient visit (60+ min)72$12,509$174
Initial hospital care with moderate level of medical decision making at least 75 minutes65$12,500$181
Hospital discharge day management, more than 30 minutes46$4,596$98
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,622$65

2021: 11 services

Original Medicare services billed in 2021
Long return visit (40+ min)133$49,037$131
Return visit (30+ min)115$25,892$88
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes86$22,224$95
Initial hospital care with moderate level of medical decision making at least 75 minutes57$11,031$184
New patient visit (60+ min)55$9,299$169
Hospital discharge day management, more than 30 minutes52$5,303$100
Long return visit (40+ min)23$3,650$111
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes34$3,402$67
Short return visit (20+ min)35$3,159$57
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes11$1,378$125
Return visit (30+ min)11$1,013$68

2020: 10 services

Original Medicare services billed in 2020
Long return visit (40+ min)124$25,333$96
Return visit (30+ min)110$22,696$72
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$11,640$98
New patient visit (60+ min)51$7,842$154
Initial hospital care with moderate level of medical decision making at least 75 minutes31$6,307$191
Short return visit (20+ min)41$3,180$48
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes23$2,945$67
Hospital discharge day management, more than 30 minutes24$2,554$102
Return visit (30+ min)17$1,860$93
Telehealth originating site facility fee14$362$20

2019: 8 services

Original Medicare services billed in 2019
Long return visit (40+ min)145$46,745$96
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes46$11,886$94
Return visit (30+ min)55$9,047$67
New patient visit (60+ min)59$8,691$147
Initial hospital care with moderate level of medical decision making at least 75 minutes44$8,443$184
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes24$2,508$66
Hospital discharge day management, more than 30 minutes22$2,182$99
Short return visit (20+ min)15$1,161$45

2018: 10 services

Original Medicare services billed in 2018
Long return visit (40+ min)121$33,989$98
Return visit (30+ min)74$12,433$69
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes47$12,077$94
New patient visit (60+ min)55$8,135$148
Initial hospital care with moderate level of medical decision making at least 75 minutes40$7,301$178
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes30$3,399$65
Hospital discharge day management, more than 30 minutes29$2,963$99
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes19$2,322$122
Hospital discharge day management, 30 minutes or less19$1,270$67
Short return visit (20+ min)12$1,014$46

2017: 9 services

Original Medicare services billed in 2017
Return visit (30+ min)96$19,639$68
Long return visit (40+ min)74$15,797$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$9,909$93
New patient visit (60+ min)51$7,379$145
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,983$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes36$4,405$65
Hospital discharge day management, more than 30 minutes31$3,142$98
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes13$1,587$122
Short return visit (20+ min)19$1,278$44

2016: 8 services

Original Medicare services billed in 2016
Long return visit (40+ min)69$11,713$95
Return visit (30+ min)75$10,635$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$8,241$93
New patient visit (60+ min)54$8,050$149
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,768$180
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes26$3,472$64
Hospital discharge day management, more than 30 minutes15$1,459$97
Hospital discharge day management, 30 minutes or less11$723$66

2015: 6 services

Original Medicare services billed in 2015
Long return visit (40+ min)64$15,659$96
Return visit (30+ min)52$7,170$67
New patient visit (60+ min)30$4,479$149
Initial hospital care with moderate level of medical decision making at least 75 minutes21$3,983$181
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$2,985$93
Hospital discharge day management, more than 30 minutes13$1,269$98

2014: 5 services

Original Medicare services billed in 2014
Long return visit (40+ min)57$12,313$93
Return visit (30+ min)63$7,868$69
New patient visit (60+ min)45$6,214$138
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,597$180
Hospital discharge day management, more than 30 minutes11$1,062$97

2013: 3 services

Original Medicare services billed in 2013
Long return visit (40+ min)54$15,290$91
New patient visit (60+ min)30$4,127$138
Return visit (30+ min)21$2,448$66

Medicaid work

$7,050 in 2024

Medicaid paid $7,050 for 90 billed services this clinician did in 2024, up to 13 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES90$7,050
Medicaid work by year
202490113$7,050
2023216425$9,862
2022168114$8,034
2021123320$4,169
202044213$1,857
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES140$5,471
Long return visit (40+ min)51$3,131
1ST HOSP IP/OBS HIGH 7512$677
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter13$583

2022

Largest Medicaid services in 2022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES168$8,034

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES93$3,124
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter13$558
Return visit (30+ min)17$486

2020

Largest Medicaid services in 2020
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES32$1,211
Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter12$645

Drugs they prescribed that Part D paid

$103,980

Pharmacies billed $103,980 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 17% of their Part D prescriptions (25 of 148) in 2024. A higher opioid share than 9 in 10 peers; the typical medical oncology clinician is at 6%.

128 generic and 20 brand-name prescriptions · $103,980 in drug cost · 20 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Levothyroxine18$200$11
Oxycodone12$100$8
Prednisone14$38$3

Year by year

Part D prescribing by year
20241484917% (25)14%$103,980
202311139NoneNone$52,101
202212142NoneNone$10,844
20211254410% (12)32%$10,200
202018945NoneNone$26,153
201917251None48%$328,318
2018255756% (16)23%$204,169
2017307627% (22)31%$643,100
201619652None42%$603,023
2015190407% (14)32%$427,974
2014153449% (14)23%$203,962
20131392519% (26)13%$42,582

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 1 drug

Part D drugs prescribed in 2023
Prednisone25$107$4

2022: 2 drugs

Part D drugs prescribed in 2022
Prednisone17$93$5
Levothyroxine11$66$6

2021: 1 drug

Part D drugs prescribed in 2021
Levothyroxine37$656$18

2020: 4 drugs

Part D drugs prescribed in 2020
Levothyroxine39$626$16
Prednisone29$324$11
Hydrocortisone12$267$22
Sulfamethoxazole-Trimethoprim16$46$3

2019: 4 drugs

Part D drugs prescribed in 2019
Mekinist11$129,506$11,773
Hydrocortisone14$352$25
Levothyroxine18$220$12
Prednisone26$159$6

2018: 7 drugs

Part D drugs prescribed in 2018
Tafinlar14$141,285$10,092
Hydrocortisone18$526$29
Valacyclovir14$436$31
Levothyroxine15$284$19
Prednisone24$187$8
Pantoprazole12$85$7
Atorvastatin12$73$6

2017: 5 drugs

Part D drugs prescribed in 2017
Mekinist27$312,163$11,562
Tafinlar27$281,347$10,420
Hydrocortisone12$513$43
Levothyroxine21$496$24
Prednisone30$174$6

2016: 5 drugs

Part D drugs prescribed in 2016
Mekinist28$288,151$10,291
Tafinlar29$268,064$9,244
Enoxaparin11$7,940$722
Hydrocortisone17$713$42
Levothyroxine13$97$7

2015: 5 drugs

Part D drugs prescribed in 2015
Mekinist22$224,966$10,226
Tafinlar22$196,538$8,934
Hydrocortisone11$343$31
Prednisone19$302$16
Levothyroxine11$118$11

2014: 2 drugs

Part D drugs prescribed in 2014
Mekinist12$116,099$9,675
Prednisone14$132$9

2013: 1 drug

Part D drugs prescribed in 2013
Lorazepam11$77$7

Money from drug and device companies

$1,785 in 2025

Industry payments by year
2025617$208$1,785
2024311None$385
2023512None$507
202223None$295
202111None$88
202036$960$1,060
2019433None$836

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
ImmunocoreKimmtrak$1,145
3 payments
  • Meals for Kimmtrak · 2025-11-14 · $100
  • Meals for Kimmtrak · 2025-10-17 · $101
  • Travel for Kimmtrak · 2025-04-23 · $944
Taiho OncologyNone$207
3 payments
  • Travel · 2025-05-31 · $47
  • Paid to speak or teach · 2025-03-29 · $124
  • Travel · 2025-02-14 · $37
AstraZeneca Pharmaceuticals LPNone$141
3 payments
  • Travel · 2025-05-31 · $32
  • Paid to speak or teach · 2025-03-29 · $84
  • Travel · 2025-02-14 · $25
PfizerNurtec Odt$125
5 payments
  • Meals for Nurtec Odt · 2025-05-02 · $26
  • Meals for Nurtec Odt · 2025-04-04 · $28
  • Meals for Nurtec Odt · 2025-03-07 · $26
  • Meals for Nurtec Odt · 2025-02-14 · $25
  • Meals for Panzyga · 2025-01-29 · $20
Regeneron PharmaceuticalsLibtayo$116
1 payment
  • Meals for Libtayo · 2025-06-26 · $116
CelgeneZeposia$51
2 payments
  • Meals for Zeposia · 2025-12-15 · $30
  • Meals for Zeposia · 2025-11-10 · $21
See all 17 published payments
Every published payment
CelgeneMeals · 2025-12-15Zeposia$30
ImmunocoreMeals · 2025-11-14Kimmtrak$100
CelgeneMeals · 2025-11-10Zeposia$21
ImmunocoreMeals · 2025-10-17Kimmtrak$101
Regeneron PharmaceuticalsMeals · 2025-06-26Libtayo$116
AstraZeneca Pharmaceuticals LPTravel · 2025-05-31None$32
Taiho OncologyTravel · 2025-05-31None$47
PfizerMeals · 2025-05-02Nurtec Odt$26
ImmunocoreTravel · 2025-04-23Kimmtrak$944
PfizerMeals · 2025-04-04Nurtec Odt$28
AstraZeneca Pharmaceuticals LPPaid to speak or teach · 2025-03-29None$84
Taiho OncologyPaid to speak or teach · 2025-03-29None$124
PfizerMeals · 2025-03-07Nurtec Odt$26
AstraZeneca Pharmaceuticals LPTravel · 2025-02-14None$25
Taiho OncologyTravel · 2025-02-14None$37
PfizerMeals · 2025-02-14Nurtec Odt$25
PfizerMeals · 2025-01-29Panzyga$20
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $385

Payments by company in 2024
PfizerNurtec Odt$231
9 payments
  • Meals for Nurtec Odt · 2024-11-12 · $28
  • Meals for Nurtec Odt · 2024-10-15 · $25
  • Meals for Nurtec Odt · 2024-08-21 · $22
  • Meals for Nurtec Odt · 2024-07-12 · $27
  • Meals for Nurtec Odt · 2024-06-08 · $25
  • Meals for Nurtec Odt · 2024-05-15 · $30
  • Meals for Nurtec Odt · 2024-04-16 · $22
  • Meals for Nurtec Odt · 2024-03-19 · $26
  • Meals for Nurtec Odt · 2024-01-23 · $28
Delcath SystemsHepzato Kit$140
1 payment
  • Meals for Hepzato Kit · 2024-07-24 · $140
Array BiopharmaBraftovi$14
1 payment
  • Meals for Braftovi · 2024-10-29 · $14

2023: $507

Payments by company in 2023
Galvanize TherapeuticsAliya System$221
1 payment
  • Meals for Aliya System · 2023-06-22 · $221
PfizerNurtec Odt$145
8 payments
  • Meals for Nurtec Odt · 2023-11-02 · $15
  • Meals for Nurtec Odt · 2023-10-26 · $18
  • Meals for Nurtec Odt · 2023-10-03 · $13
  • Meals for Nurtec Odt · 2023-09-09 · $15
  • Meals for Nurtec Odt · 2023-08-08 · $21
  • Meals for Nurtec Odt · 2023-07-06 · $24
  • Meals for Nurtec Odt · 2023-05-25 · $22
  • Meals for Panzyga · 2023-04-11 · $17
TriSalus Life SciencesTrinav Infusion System$101
1 payment
  • Meals for Trinav Infusion System · 2023-06-05 · $101
E.R. Squibb & Sons L.L.C.None$23
1 payment
  • Meals · 2023-10-17 · $23
Array BiopharmaBraftovi$18
1 payment
  • Meals for Braftovi · 2023-03-14 · $18

2022: $295

Payments by company in 2022
E.R. Squibb & Sons L.L.C.Opdivo$186
2 payments
  • Meals for Opdivo · 2022-11-16 · $94
  • Meals for Opdivo · 2022-05-17 · $93
ImmunocoreKimmtrak$109
1 payment
  • Meals for Kimmtrak · 2022-10-24 · $109

2021: $88

Payments by company in 2021
E.R. Squibb & Sons L.L.C.Opdivo$88
1 payment
  • Meals for Opdivo · 2021-09-08 · $88

2020: $1,060

Payments by company in 2020
Varian Medical SystemsNone$960
1 payment
  • Consulting · 2020-05-20 · $960
EMD SeronoMavenclad$76
4 payments
  • Meals for Mavenclad · 2020-04-09 · $22
  • Meals for Mavenclad · 2020-02-13 · $16
  • Meals for Mavenclad · 2020-01-16 · $18
  • Meals for Mavenclad · 2020-01-02 · $21
EisaiLenvima$24
1 payment
  • Meals for Lenvima · 2020-09-15 · $24

2019: $836

Payments by company in 2019
EMD SeronoMavenclad$372
29 payments
  • Meals for Mavenclad · 2019-12-05 · $14
  • Meals for Mavenclad · 2019-11-21 · $22
  • Meals for Mavenclad · 2019-11-05 · $14
  • Meals for Mavenclad · 2019-10-24 · $18
  • Meals for Mavenclad · 2019-10-10 · $19
  • Meals for Mavenclad · 2019-10-03 · $15
  • Meals for Rebif · 2019-10-03 · $1
  • Meals for Mavenclad · 2019-09-12 · $15
  • Education · 2019-09-03 · $7
  • Meals for Mavenclad · 2019-08-23 · $16
  • Meals for Mavenclad · 2019-08-08 · $17
  • Meals for Mavenclad · 2019-07-25 · $14
  • Meals for Rebif · 2019-07-25 · $3
  • Meals for Mavenclad · 2019-07-11 · $14
  • Meals for Mavenclad · 2019-07-01 · $14
  • Meals for Mavenclad · 2019-06-12 · $10
  • Meals for Mavenclad · 2019-06-06 · $17
  • Meals for Mavenclad · 2019-05-23 · $19
  • Meals for Mavenclad · 2019-05-09 · $18
  • Meals for Mavenclad · 2019-04-25 · $20
  • Meals for Mavenclad · 2019-04-12 · $2
  • Meals for Mavenclad · 2019-04-11 · $12
  • Meals for Rebif · 2019-03-28 · $17
  • Meals for Rebif · 2019-03-07 · $13
  • Meals for Rebif · 2019-02-14 · $20
  • Meals for Rebif · 2019-02-12 · $10
  • Meals for Rebif · 2019-02-06 · $1
  • Meals for Rebif · 2019-01-31 · $9
  • Meals for Rebif · 2019-01-31 · $1
Array BioPharmaBraftovi$160
1 payment
  • Meals for Braftovi · 2019-04-10 · $160
E.R. Squibb & Sons L.L.C.Opdivo$157
2 payments
  • Meals for Opdivo · 2019-06-04 · $35
  • Meals · 2019-04-04 · $122
NovocureOncology$147
1 payment
  • Meals for Oncology · 2019-04-30 · $147

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2024Their institution$353,806
TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2023Their institution$293,629
TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2025Their institution$197,466
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2019Their institution$118,500
Genentech, Inc. · A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients · 2020Their institution$46,929
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2020Their institution$45,518
Genentech, Inc. · A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients · 2019Their institution$45,292
E.R. Squibb & Sons, L.L.C. · Phase III 1l Melanoma Non-Inferiority Rela+Nivo Fdc Subq Vs. Rela+Nivo Fdc IV · 2024Their institution$33,012
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2021Their institution$32,656
E.R. Squibb & Sons, L.L.C. · Phiii Stage 3/4 Resectable Mel Adj Rela+Nivo Vs Nivo - A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Relatlimab Andnivolumab Fixed-Dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma [ · 2023Their institution$28,493
E.R. Squibb & Sons, L.L.C. · Phase III 1l Melanoma Non-Inferiority Rela+Nivo Fdc Subq Vs. Rela+Nivo Fdc IV · 2023Their institution$25,737
Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2019Their institution$23,714
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open-Label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-Dose Combination in Participants With Previously Untreated Metastatic Or Unresectable Melanoma · 2025Their institution$17,382
Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2021Their institution$17,225
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2022Their institution$11,008
Incyte Corporation · A Phase 2 Study of Incmga00012 in Participants With Metastatic Merkel Cell Carcinoma · 2020Their institution$10,260
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2020Their institution$9,678
TriSalus Life Sciences, Inc. · Ts-Perio-01 · 2022Their institution$7,269
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2021Their institution$3,737
Merck Sharp & Dohme LLC · A Phase II Trial of Mk3475 in Merkel Cell Carcinoma Mcc · 2022Their institution$2,409
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2022Their institution$1,827
Novartis Pharmaceuticals Corporation · A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma · 2023Their institution$1,355
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2024Their institution$575
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2022Their institution$490
E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Open-Label Study of Nktr-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable Or Metastatic Melanoma · 2025Their institution$373
E.R. Squibb & Sons, L.L.C. · Phiii Stage 3 4 Resectable Mel Adj Rela Nivo Vs Nivo · 2021Their institution$263
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo Nktr 214 Vs Nivo Mono · 2019Their institution$149
E.R. Squibb & Sons, L.L.C. · Ph III 1l Metastatic Melanoma Nivo+Nktr 214 Vs Nivo Mono · 2023Their institution$38

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1578645057
Licence
CA A61643California A61643: Current · expires 2028-08-31
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2006-10-20
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 5725 W Las Positas Blvd, Pleasanton, CA, 94588